Renaissance Technologies’s BioCardia BCDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-13,900
Closed -$16.8K 3205
2026
Q1
$16.8K Buy
+13,900
New +$17.4K ﹤0.01% 3180
2024
Q1
Sell
-5,887
Closed -$59K 3707
2023
Q4
$59K Buy
5,887
+5,187
+741% +$42.1K ﹤0.01% 3425
2023
Q3
$5K Sell
700
-480
-41% -$8.08K ﹤0.01% 3600
2023
Q2
$47K Buy
1,180
+140
+13% +$4.31K ﹤0.01% 3626
2023
Q1
$30K Buy
1,040
+100
+11% +$3.32K ﹤0.01% 3757
2022
Q4
$29K Sell
940
-13
-1% -$370 ﹤0.01% 3894
2022
Q3
$28K Sell
953
-34
-3% -$879 ﹤0.01% 3854
2022
Q2
$21K Buy
987
+74
+8% +$1.77K ﹤0.01% 4110
2022
Q1
$28K Buy
+913
New +$27.1K ﹤0.01% 3977
2021
Q4
Sell
-2,903
Closed -$137K 3893
2021
Q3
$137K Sell
2,903
-3,912
-57% -$192K ﹤0.01% 3276
2021
Q2
$406K Sell
6,815
-13,532
-67% -$822K ﹤0.01% 3040
2021
Q1
$1.32M Buy
+20,347
New +$1.27M ﹤0.01% 2475

Other funds holding BCDA

Renaissance Technologies's BCDA Position: Q2 2026 in Review

Renaissance Technologies sold out of BioCardia (BCDA) in Q2 2026, closing a stake of 13,900 shares — an estimated $16.8K sold.

Renaissance Technologies first reported a position in BCDA in Q1 2021 and held it in 12 quarters. The position peaked at $1.32M in Q1 2021. 21 funds tracked by Wall St. Rank hold BCDA as of Q2 2026.

  • Renaissance Technologies reported no remaining BioCardia position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 13,900 BioCardia shares in Q2 2026, an estimated $16.8K.
  • Renaissance Technologies first reported a position in BioCardia in Q1 2021 and held it in 12 quarters.
  • Renaissance Technologies's BioCardia position peaked at $1.32M in Q1 2021.
  • 21 funds tracked by Wall St. Rank held BioCardia as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.